buyModerate
Mark C. McKenna bought $991k of APGE
director at Apogee Therapeutics, Inc.. 20,000 shares at an average of $49.54, traded Dec 12, 2024, filed Dec 16, 2024.
Conviction score
48Value
$991k
20,000 shares
Holdings after
20,000
change unknown
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +25Trade size$991k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-24-128588, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 12, 2024 | POpen-market purchase Common Stock | +7,500 | $49.02 | $368k | 7,500 | Dec 16, 2024 |
| Dec 12, 2024 | POpen-market purchase Common Stock | +12,500 | $49.85 | $623k | 20,000 | Dec 16, 2024 |
Related signals
Other insiders at Apogee Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 5Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $103k 2,725 shares | -1% | |
| 5Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $103k 2,725 shares | -1% | |
| 0Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $455k 10,090 shares | -4% | |
| 5Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $101k 2,725 shares | -1% | |
| 5Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $97k 2,725 shares | -1% | |
| 6Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $140k 3,860 shares | -2% | |
| 27Weak | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $302k 10,000 shares | -1% | |
| 10Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $48k 1,590 shares | -1% | |
| 33Weak | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $609k 15,000 shares | -1% | |
| 0Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $143k 3,520 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.